Biogen Inches Higher On Third-Quarter Beat, But All Eyes Watch Alzheimer's DrugInvestors Business Daily • 10/25/22
Biogen Announces FDA's 3-Month Extension of Review Period for the New Drug Application for TofersenGlobeNewsWire • 10/17/22
Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) CongressBusiness Wire • 10/17/22
Biogen Soars On Upgrade; Why Lilly, Roche Won't Block Its Alzheimer's OpportunityInvestors Business Daily • 10/13/22
SHAREHOLDER ALERT: Biogen Inc. (BIIB) Officers and Directors Under Investigation for Possible False Statements About AduhelmPRNewsWire • 10/13/22
GoodRx and Biogen Collaborate to Help Enhance Enrollment Experience for Providers Who Have Chosen to Start Multiple Sclerosis Patients on VUMERITY®Business Wire • 10/13/22
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/12/22
These Are The Five Best And Worst Performing Large-Cap Stocks In September 202224/7 Wall Street • 10/10/22